HomeCompareRPGHF vs ABBV

RPGHF vs ABBV: Dividend Comparison 2026

RPGHF yields 118.34% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 RPGHF wins by $7.92M in total portfolio value
10 years
RPGHF
RPGHF
● Live price
118.34%
Share price
$1.69
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$8.03M
Annual income
$3,014,923.49
Full RPGHF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — RPGHF vs ABBV

📍 RPGHF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodRPGHFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, RPGHF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
RPGHF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

RPGHF
Annual income on $10K today (after 15% tax)
$10,059.17/yr
After 10yr DRIP, annual income (after tax)
$2,562,684.97/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, RPGHF beats the other by $2,541,628.96/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of RPGHF + ABBV for your $10,000?

RPGHF: 50%ABBV: 50%
100% ABBV50/50100% RPGHF
Portfolio after 10yr
$4.06M
Annual income
$1,519,847.63/yr
Blended yield
37.39%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

RPGHF
No analyst data
Altman Z
9.1
Piotroski
7/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

RPGHF buys
0
ABBV buys
0
No recent congressional trades found for RPGHF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricRPGHFABBV
Forward yield118.34%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$8.03M$102.3K
Annual income after 10y$3,014,923.49$24,771.77
Total dividends collected$7.29M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: RPGHF vs ABBV ($10,000, DRIP)

YearRPGHF PortfolioRPGHF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$22,534$11,834.32$11,550$430.00+$11.0KRPGHF
2$49,035$24,923.21$13,472$627.96+$35.6KRPGHF
3$103,153$50,685.22$15,906$926.08+$87.2KRPGHF
4$210,022$99,648.81$19,071$1,382.55+$191.0KRPGHF
5$414,339$189,615.20$23,302$2,095.81+$391.0KRPGHF
6$792,949$349,606.93$29,150$3,237.93+$763.8KRPGHF
7$1,473,753$625,296.70$37,536$5,121.41+$1.44MRPGHF
8$2,663,044$1,086,129.08$50,079$8,338.38+$2.61MRPGHF
9$4,683,678$1,834,220.22$69,753$14,065.80+$4.61MRPGHF
10$8,026,459$3,014,923.49$102,337$24,771.77+$7.92MRPGHF

RPGHF vs ABBV: Complete Analysis 2026

RPGHFStock

RPMGlobal Holdings Limited develops and provides mining software solutions in Australia, Asia, the Americas, Africa, and Europe. It operates through Software and Advisory divisions. The company provides software licensing, consulting, implementation, and support services; and technical, advisory, and training services. It also offers enterprise planning framework; Open Cut Phosphate, Open Pit Metals, Open Pit Diamond, Quarry, and Steep coal solutions; RESERVER, a mine reserve model; EmissionsManager, a SaaS based solution for collecting, calculating, monitoring, and reporting emissions data; XECUTE that enables planners to build a term schedule; Asset Management; XPAC solution, a scheduling software; XACT, a short-term mining operation solution, as well as Enterprise Optimiser; IMAFS, which uses AI to enhance inventory management; and Schedule Optimisation Tool for scenario planning and comparisons. In addition, the company provides Attain, a flexible mine schedule optimization tool; Strategic Design Optimiser; Stratigraphic metal solution; underground metals solution; underground coal solution; underground potash solution; product optimizer; HAULSIM, a 3-D discrete event simulation software; SIMULATE, an event simulation software for original equipment manufacturers; TALPAC-3D, a truck and loader productivity calculator; TALPAC, a truck and loader productivity solution for underground coal mines; Open Cut Coal solution; and DRAGSIM, a dragline simulation software. Further, it offers XERAS Enterprise, a budgeting solution; XERAS, a financial modelling solution; ShiftManager, a mine engineering and shift management software; MINVU, a mining management software; and AMT, an asset maintenance software for contractors and OEMs, as well as AMT4SAP. The company was formerly known as RungePincockMinarco Limited and changed its name to RPMGlobal Holdings Limited in March 2017. RPMGlobal Holdings Limited was founded in 1968 and is headquartered in Brisbane, Australia.

Full RPGHF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this RPGHF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

RPGHF vs SCHDRPGHF vs JEPIRPGHF vs ORPGHF vs KORPGHF vs MAINRPGHF vs JNJRPGHF vs MRKRPGHF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.